运动训练对1型发作性睡病睡眠症状和合并症的可行性和有效性：一项前瞻性介入研究

IF 4.9 2区医学 Q1 Medicine

Sleep Pub Date : 2025-09-10 DOI:10.1093/sleep/zsaf272

François Ricordeau, Emeric Stauffer, Benjamin Putois, Antoine Jaffiol, Anne Cheylus, Gabrielle Pouilloux, Kenny Gabriel, Eugénie Hoarau, Hélène Bastuji, Patricia Franco, Vania Herbillon, Thomas Capelle, Fanny Joubert, Pierre Pradat, Karine Spiegel, Laure Peter-Derex

{"title":"运动训练对1型发作性睡病睡眠症状和合并症的可行性和有效性：一项前瞻性介入研究","authors":"François Ricordeau, Emeric Stauffer, Benjamin Putois, Antoine Jaffiol, Anne Cheylus, Gabrielle Pouilloux, Kenny Gabriel, Eugénie Hoarau, Hélène Bastuji, Patricia Franco, Vania Herbillon, Thomas Capelle, Fanny Joubert, Pierre Pradat, Karine Spiegel, Laure Peter-Derex","doi":"10.1093/sleep/zsaf272","DOIUrl":null,"url":null,"abstract":"Current treatments for narcolepsy type 1 (NT1) have little impact on psychiatric, cognitive and metabolic comorbidities. Here, we evaluated the feasibility, safety and efficacy of a prospective Exercise Training (ET) program on sleep-related symptoms and comorbidities in NT1. Sedentary adult with NT1 participated in a 6-week supervised ET program followed by a 18-week self-directed program. Outcomes included the Narcolepsy Severity Scale (NSS), Hospital Anxiety and Depression Scale (HADS), Insomnia Severity Index (ISI), cardiometabolic parameters (body mass index [BMI], glycemia, insulin, CRP, lipid panel with insulin resistance [IR] [TG/HDL-C] and cardiovascular risk [Total-C/HDL-C] markers), cardiorespiratory fitness, and attention (Bron/Lyon Attention Stability Test). Wilcoxon tests compared baseline, 6-week, and 6-month data. Among 30 participants (73.3% women, 39.8±13.9 years, BMI=31.0±5.1 kg/m2), 25 completed the 6-month program. Of the 379 supervised sessions (84.2% attendance), only 7 partial cataplexies occurred. At 6 weeks, significant improvements were observed in median[IQR] NSS (-2.0[-4.0;0], p=0.046), ISI (-1.0[-3.0;1.0], p=0.050), triglycerides (-0.21[-0.46;-0.09]g/L, p=0.015), IR (-0.19[-0.46;-0.04], p=0,003), cardiorespiratory fitness ((+15.0[5.0;20.0]watts, p<0.001), and in most attention scores (stability, intensity, reaction time: p<0.05). At 6 months, NSS and ISI changes were no longer significant but anxiety (-1.0[-3.0;1.0], p=0.041) and depression (-2.0[-4.0;0.0], p=0.004) decreased. Improvements in IR (-0.27[-0.44;-0.11], p=0.002), triglycerides (-0.2[-0.4;0.0]g/L, p=0.033), cardiovascular risk (-0.16[-0.41;-0.02], p=0,019), and attention scores (intensity, reaction time, number of errors p<0.05) were sustained. VO2max and BMI showed no significant changes. Physical activity is feasible and safe in NT1, enabling improvements in narcolepsy symptoms, anxiety/depression, cognition, and cardiometabolic markers. Larger randomized controlled trials are needed to confirm these findings.","PeriodicalId":22018,"journal":{"name":"Sleep","volume":" ","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Feasibility and efficacy of exercise training on sleep symptoms and comorbidities in narcolepsy type 1: a prospective interventional study.\",\"authors\":\"François Ricordeau, Emeric Stauffer, Benjamin Putois, Antoine Jaffiol, Anne Cheylus, Gabrielle Pouilloux, Kenny Gabriel, Eugénie Hoarau, Hélène Bastuji, Patricia Franco, Vania Herbillon, Thomas Capelle, Fanny Joubert, Pierre Pradat, Karine Spiegel, Laure Peter-Derex\",\"doi\":\"10.1093/sleep/zsaf272\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Current treatments for narcolepsy type 1 (NT1) have little impact on psychiatric, cognitive and metabolic comorbidities. Here, we evaluated the feasibility, safety and efficacy of a prospective Exercise Training (ET) program on sleep-related symptoms and comorbidities in NT1. Sedentary adult with NT1 participated in a 6-week supervised ET program followed by a 18-week self-directed program. Outcomes included the Narcolepsy Severity Scale (NSS), Hospital Anxiety and Depression Scale (HADS), Insomnia Severity Index (ISI), cardiometabolic parameters (body mass index [BMI], glycemia, insulin, CRP, lipid panel with insulin resistance [IR] [TG/HDL-C] and cardiovascular risk [Total-C/HDL-C] markers), cardiorespiratory fitness, and attention (Bron/Lyon Attention Stability Test). Wilcoxon tests compared baseline, 6-week, and 6-month data. Among 30 participants (73.3% women, 39.8±13.9 years, BMI=31.0±5.1 kg/m2), 25 completed the 6-month program. Of the 379 supervised sessions (84.2% attendance), only 7 partial cataplexies occurred. At 6 weeks, significant improvements were observed in median[IQR] NSS (-2.0[-4.0;0], p=0.046), ISI (-1.0[-3.0;1.0], p=0.050), triglycerides (-0.21[-0.46;-0.09]g/L, p=0.015), IR (-0.19[-0.46;-0.04], p=0,003), cardiorespiratory fitness ((+15.0[5.0;20.0]watts, p<0.001), and in most attention scores (stability, intensity, reaction time: p<0.05). At 6 months, NSS and ISI changes were no longer significant but anxiety (-1.0[-3.0;1.0], p=0.041) and depression (-2.0[-4.0;0.0], p=0.004) decreased. Improvements in IR (-0.27[-0.44;-0.11], p=0.002), triglycerides (-0.2[-0.4;0.0]g/L, p=0.033), cardiovascular risk (-0.16[-0.41;-0.02], p=0,019), and attention scores (intensity, reaction time, number of errors p<0.05) were sustained. VO2max and BMI showed no significant changes. Physical activity is feasible and safe in NT1, enabling improvements in narcolepsy symptoms, anxiety/depression, cognition, and cardiometabolic markers. Larger randomized controlled trials are needed to confirm these findings.\",\"PeriodicalId\":22018,\"journal\":{\"name\":\"Sleep\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.9000,\"publicationDate\":\"2025-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sleep\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/sleep/zsaf272\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sleep","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/sleep/zsaf272","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

目前治疗1型发作性睡病（NT1）对精神、认知和代谢合并症的影响很小。在这里，我们评估了前瞻性运动训练（ET）计划对NT1患者睡眠相关症状和合并症的可行性、安全性和有效性。久坐的患有NT1的成年人参加了一个为期6周的有监督的ET项目，随后是一个为期18周的自我指导项目。结果包括发作性睡严重程度量表（NSS）、医院焦虑和抑郁量表（HADS）、失眠严重程度指数（ISI）、心脏代谢参数（体重指数[BMI]、血糖、胰岛素、CRP、伴有胰岛素抵抗的脂质面板[IR] [TG/HDL-C]和心血管风险[Total-C/HDL-C]标志物）、心肺健康和注意力（Bron/Lyon注意力稳定性测试）。Wilcoxon试验比较了基线、6周和6个月的数据。在30名参与者中（73.3%女性，39.8±13.9岁，BMI=31.0±5.1 kg/m2）， 25人完成了6个月的计划。在379次有监督的会议（84.2%出席）中，只有7次发生了部分性中风。6周时，观察到中位[IQR] NSS （-2.0[-4.0;0], p=0.046）、ISI （-1.0[-3.0;1.0], p=0.050）、甘油三酯（-0.21[-0.46;-0.09]g/L, p=0.015）、IR （-0.19[-0.46;-0.04], p= 0.003）、心肺适能（+15.0[5.0;20.0]watts, p=0.015）显著改善

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Feasibility and efficacy of exercise training on sleep symptoms and comorbidities in narcolepsy type 1: a prospective interventional study.

Current treatments for narcolepsy type 1 (NT1) have little impact on psychiatric, cognitive and metabolic comorbidities. Here, we evaluated the feasibility, safety and efficacy of a prospective Exercise Training (ET) program on sleep-related symptoms and comorbidities in NT1. Sedentary adult with NT1 participated in a 6-week supervised ET program followed by a 18-week self-directed program. Outcomes included the Narcolepsy Severity Scale (NSS), Hospital Anxiety and Depression Scale (HADS), Insomnia Severity Index (ISI), cardiometabolic parameters (body mass index [BMI], glycemia, insulin, CRP, lipid panel with insulin resistance [IR] [TG/HDL-C] and cardiovascular risk [Total-C/HDL-C] markers), cardiorespiratory fitness, and attention (Bron/Lyon Attention Stability Test). Wilcoxon tests compared baseline, 6-week, and 6-month data. Among 30 participants (73.3% women, 39.8±13.9 years, BMI=31.0±5.1 kg/m2), 25 completed the 6-month program. Of the 379 supervised sessions (84.2% attendance), only 7 partial cataplexies occurred. At 6 weeks, significant improvements were observed in median[IQR] NSS (-2.0[-4.0;0], p=0.046), ISI (-1.0[-3.0;1.0], p=0.050), triglycerides (-0.21[-0.46;-0.09]g/L, p=0.015), IR (-0.19[-0.46;-0.04], p=0,003), cardiorespiratory fitness ((+15.0[5.0;20.0]watts, p<0.001), and in most attention scores (stability, intensity, reaction time: p<0.05). At 6 months, NSS and ISI changes were no longer significant but anxiety (-1.0[-3.0;1.0], p=0.041) and depression (-2.0[-4.0;0.0], p=0.004) decreased. Improvements in IR (-0.27[-0.44;-0.11], p=0.002), triglycerides (-0.2[-0.4;0.0]g/L, p=0.033), cardiovascular risk (-0.16[-0.41;-0.02], p=0,019), and attention scores (intensity, reaction time, number of errors p<0.05) were sustained. VO2max and BMI showed no significant changes. Physical activity is feasible and safe in NT1, enabling improvements in narcolepsy symptoms, anxiety/depression, cognition, and cardiometabolic markers. Larger randomized controlled trials are needed to confirm these findings.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Sleep Medicine-Neurology (clinical)

CiteScore

8.70

自引率

10.70%

发文量

期刊介绍： SLEEP® publishes findings from studies conducted at any level of analysis, including: Genes Molecules Cells Physiology Neural systems and circuits Behavior and cognition Self-report SLEEP® publishes articles that use a wide variety of scientific approaches and address a broad range of topics. These may include, but are not limited to: Basic and neuroscience studies of sleep and circadian mechanisms In vitro and animal models of sleep, circadian rhythms, and human disorders Pre-clinical human investigations, including the measurement and manipulation of sleep and circadian rhythms Studies in clinical or population samples. These may address factors influencing sleep and circadian rhythms (e.g., development and aging, and social and environmental influences) and relationships between sleep, circadian rhythms, health, and disease Clinical trials, epidemiology studies, implementation, and dissemination research.